Generic placeholder image

Current Cancer Therapy Reviews


ISSN (Print): 1573-3947
ISSN (Online): 1875-6301

Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable

Author(s): Robert P. Hasserjian

Volume 8, Issue 1, 2012

Page: [14 - 29] Pages: 16

DOI: 10.2174/157339412799462495

Price: $65


Myeloproliferative neoplasms (MPNs) are clonal bone marrow (BM) proliferations that most often manifest as increased peripheral blood (PB) counts and/or splenomegaly. Unlike myelodysplastic syndromes, the hemopoiesis in MPN is effective, leading to the increased peripheral counts; unlike the acute leukemias, there is intact maturation of all hematopoietic lineages. The main MPN entities discussed in this chapter are polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The uncommon MPN entities of chronic neutrophilic leukemia and unclassifiable MPN are also discussed. An activating point mutation in the JAK2 gene underlies the pathogenesis of many MPN, including almost all cases of polycythemia vera and about half of essential thrombocythemia and primary myelofibrosis cases. Accurate diagnosis of MPN involves distinguishing these neoplasms from reactive causes of increased PB counts as well as appropriate classification of MPN into specific entities. The diagnosis of MPN requires an integration of clinical features, BM morphology, and genetic tests, in particular JAK2 mutation analysis. Therapeutic approaches, including targeted therapy as pertinent, are also discussed for each entity.

Keywords: Myeloproliferative neoplasm, polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic idiopathic myelofibrosis, myeloid metaplasia, chronic neutrophilic leukemia, JAK2

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy